Clinical Trial

A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

Name: A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) — clinical trial record (NCT07618325)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

The purpose of this study is to elucidate the molecular mechanism by which novel adjuvants enhance the immunogenicity of Respiratory Syncytial Virus (RSV) vaccines by regulating antigen-specific B cell affinity maturation and T cell memory formation.

Trial Details

NCT Number	NCT07618325
Lead Sponsor	MAXVAX Biotechnology Limited Liability Company Collaborators: Henan Center for Disease Control and Prevention
Conditions	Respiratory Syncytial Virus (RSV)
Enrollment	60 participants
Start Date	2026-06-02
Primary Completion	2028-06-30 (estimated)
Study Completion	2028-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-01